<--- Back to Details
First PageDocument Content
Date: 2017-03-27 02:02:40

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

Add to Reading List

Source URL: www.biolinerx.com

Download Document from Source Website

File Size: 915,67 KB

Share Document on Facebook

Similar Documents